{"id":38286,"date":"2021-11-02T17:27:07","date_gmt":"2021-11-02T21:27:07","guid":{"rendered":"https:\/\/www.arisglobal.com\/?p=38286"},"modified":"2021-11-02T17:27:07","modified_gmt":"2021-11-02T21:27:07","slug":"arisglobals-2021-state-of-the-industry-report-explores-automation-adoption","status":"publish","type":"post","link":"https:\/\/www.arisglobal.com\/media\/press-release\/arisglobals-2021-state-of-the-industry-report-explores-automation-adoption\/","title":{"rendered":"ArisGlobal’s “2021 State of the Industry Report” Explores Automation Adoption"},"content":{"rendered":"

Report reveals how life sciences companies currently use automation and the potential of technological adoption within the industry<\/em><\/strong><\/p>\n

MIAMI \u2014 November 2, 2021 \u2014<\/strong> ArisGlobal<\/a>, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere\u00ae<\/sup>, recently released its 2021 State of the Industry Repor<\/a>t<\/a>, revealing how life sciences companies are currently using automation and showcasing the potential of technological adoption within the industry. ArisGlobal surveyed various industry subject matter experts from emerging, mid-sized, and large organizations, including CROs, service providers, and consultants from the pharmaceutical, medical device, and biotechnology arenas.<\/p>\n

ArisGlobal\u2019s report found that the vast majority of survey respondents, 83%, said their organizations use some form of automation across their R&D processes, whether automating specific processes with rule-based automation or deploying more advanced technologies. While the deployment of rule-based automation is typical, report data shows that the advanced use of automation lags across all life sciences segments. A small selection of survey respondents, 4%, revealed that their organizations currently use advanced technology, such as machine learning (ML) or natural language processing (NLP).<\/p>\n

\u201cAdoption of automation is increasing as companies realize the opportunities that exist. The industry is starting to see the value of advanced technologies like cognitive automation, machine learning, and data fabric,\u201d said Sankesh Abbhi, CEO of ArisGlobal. \u201cOur report finds that automation is happening all across the life sciences R&D journey, with drug safety being the most mature and other functions primed to catch up. The future will be exciting to watch, and we will continue to enable companies to realize the benefits of automation through our LifeSphere platform.\u201d<\/p>\n

Top benefits from adopting and implementing automation technology included cost savings through efficiency gains and improved quality compliance. Respondents also expected to achieve deeper insights to support enhanced decision making, streamlined cross-functional collaboration, and increased flexibility and scalability.<\/p>\n

According to the State of the Industry<\/a> report, process integration of automation is the primary concern of survey respondents when integrating new technology with existing technology. ArisGlobal\u2019s report found that 46% of respondents are concerned about quantifying the benefits of automation. Lengthy implementation timelines also pose a challenge.<\/p>\n

Additional highlights from ArisGlobal\u2019s 2021 State of the Industry Report:<\/strong><\/p>\n